<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00009854</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068416</org_study_id>
    <secondary_id>DTI-0002</secondary_id>
    <secondary_id>UCSF-H7858-17520-01</secondary_id>
    <secondary_id>NCI-V00-1642</secondary_id>
    <nct_id>NCT00009854</nct_id>
  </id_info>
  <brief_title>Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm</brief_title>
  <official_title>Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direct Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of carmustine followed by surgery in&#xD;
      treating patients who have recurrent supratentorial malignant glioma or metastatic brain&#xD;
      neoplasm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the extent and pattern of distribution of DNA adducts in patients with&#xD;
           recurrent supratentorial malignant glioma or metastatic neoplasm to the brain treated&#xD;
           with neoadjuvant intratumoral carmustine in ethanol (DTI-015) followed by tumor&#xD;
           resection.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxicity of this treatment regimen in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      Patients receive neoadjuvant carmustine in ethanol (DTI-015) intratumorally under&#xD;
      stereotactic guidance 45-90 minutes prior to craniotomy and tumor resection.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of DTI-015 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 3 or 3 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 4, 8, and 12 weeks, and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2000</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine in ethanol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent supratentorial malignant glioma with clear evidence&#xD;
             of progression by MRI&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Anaplastic ependymoma&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma OR&#xD;
&#xD;
          -  Metastatic tumor to the brain other than melanoma&#xD;
&#xD;
          -  Planned resection of tumor (must be first surgery for recurrent disease)&#xD;
&#xD;
          -  Tumor volume of each tumor component or residual tumor must be at least 4 cm3 and no&#xD;
             greater than 33.4 cm3&#xD;
&#xD;
          -  Tumor shape and surrounding structure(s) unlikely to cause an irregular distribution&#xD;
             of the injected study drug&#xD;
&#xD;
               -  Tumor is spherical, spheroid, or ovoid&#xD;
&#xD;
               -  No tumors shaped into 3 or more components (e.g., multicentric or multilobulated)&#xD;
&#xD;
               -  No tumors extending into the ventricular system&#xD;
&#xD;
               -  Tumor has an intact stroma (i.e., tumor mass not partially incised or punctured)&#xD;
&#xD;
               -  Central necrosis and/or central cystic areas allowed if an enhancing rim with a&#xD;
                  thickness of more than 5 mm is present&#xD;
&#xD;
          -  No tumors in the following locations of the brain:&#xD;
&#xD;
               -  Brainstem (pons or medulla)&#xD;
&#xD;
               -  Midbrain (mesencephalon)&#xD;
&#xD;
               -  Primary sensorimotor cortex in the dominant hemisphere&#xD;
&#xD;
               -  Within 1.5 cm of the optic chiasm, either optic nerve, or any other cranial nerve&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No evidence of bleeding diathesis&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 40 mL/min OR&#xD;
&#xD;
          -  BUN no greater than 30 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  Afebrile (37.5 degrees C) unless fever due to tumor&#xD;
&#xD;
          -  No other unstable or severe medical condition&#xD;
&#xD;
          -  No complicating medical or psychiatric problem that would preclude study&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas,&#xD;
             mitomycin, or Gliadel wafers) and recovered&#xD;
&#xD;
          -  No anti-tumor chemotherapy within 12 weeks after study drug unless tumor volume&#xD;
             increases by more than 25% by MRI&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior intracranial brachytherapy&#xD;
&#xD;
          -  No anti-tumor radiotherapy within 12 weeks after study drug unless tumor volume&#xD;
             increases by more than 25% by MRI&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior surgery allowed&#xD;
&#xD;
          -  No anti-tumor surgery within 12 weeks after study drug&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gene David Resnick, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Millennix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>adult glioblastoma</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

